Acrivon Therapeutics (NASDAQ:ACRV) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Acrivon Therapeutics (NASDAQ:ACRV) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

Several other research firms have also issued reports on ACRV. Weiss Ratings reissued a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 15th. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.00.

Acrivon Therapeutics Stock Performance

Shares of ACRV opened at $2.16 on Friday. Acrivon Therapeutics has a 52-week low of $1.05 and a 52-week high of $8.00. The stock’s 50-day simple moving average is $2.19 and its 200 day simple moving average is $1.69. The stock has a market capitalization of $68.17 million, a price-to-earnings ratio of -1.01 and a beta of 1.75.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.10. On average, research analysts forecast that Acrivon Therapeutics will post -2.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen LLC purchased a new stake in Acrivon Therapeutics during the first quarter valued at about $27,000. Quadrature Capital Ltd bought a new position in Acrivon Therapeutics during the 2nd quarter worth approximately $26,000. UBS Group AG increased its stake in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares during the period. Focus Partners Wealth bought a new position in shares of Acrivon Therapeutics in the third quarter worth approximately $36,000. Finally, Algert Global LLC bought a new stake in Acrivon Therapeutics during the 3rd quarter valued at $81,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.